GNA Biosolutions closes $13.5M Series C round
GNA Biosolutions GmbH, a molecular diagnostics company based in Germany, announced today that it has completed a $13.5M round of financing. Proceeds from the financing will be used to advance development and secure IVD-CE marking of GNA’s first Point of Care molecular diagnostic platform.
The Series C financing round was joined by new investors including GreyBird Ventures, Occident, and Wachtumsfonds Bayern, and existing investors like btov Partners.
Read more in the official press release here.